Browse TLR7

Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type I membrane protein Endosome Lysosome Cytoplasmic vesicle, phagosome Note=Relocalizes from endoplasmic reticulum to endosome and lysosome upon stimulation with agonist.
Domain PF13306 Leucine rich repeats (6 copies)
PF13855 Leucine rich repeat
PF01582 TIR domain
Function

Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 is a nucleotide-sensing TLR which is activated by single-stranded RNA. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (By similarity).

> Gene Ontology
 
Biological Process GO:0001774 microglial cell activation
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002274 myeloid leukocyte activation
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007252 I-kappaB phosphorylation
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0017038 protein import
GO:0031349 positive regulation of defense response
GO:0031503 protein complex localization
GO:0032103 positive regulation of response to external stimulus
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032602 chemokine production
GO:0032606 type I interferon production
GO:0032607 interferon-alpha production
GO:0032608 interferon-beta production
GO:0032609 interferon-gamma production
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032642 regulation of chemokine production
GO:0032647 regulation of interferon-alpha production
GO:0032648 regulation of interferon-beta production
GO:0032649 regulation of interferon-gamma production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032722 positive regulation of chemokine production
GO:0032727 positive regulation of interferon-alpha production
GO:0032728 positive regulation of interferon-beta production
GO:0032729 positive regulation of interferon-gamma production
GO:0032755 positive regulation of interleukin-6 production
GO:0032757 positive regulation of interleukin-8 production
GO:0033157 regulation of intracellular protein transport
GO:0034154 toll-like receptor 7 signaling pathway
GO:0034162 toll-like receptor 9 signaling pathway
GO:0034504 protein localization to nucleus
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042116 macrophage activation
GO:0042228 interleukin-8 biosynthetic process
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042346 positive regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0044744 protein targeting to nucleus
GO:0045072 regulation of interferon-gamma biosynthetic process
GO:0045078 positive regulation of interferon-gamma biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045349 interferon-alpha biosynthetic process
GO:0045350 interferon-beta biosynthetic process
GO:0045351 type I interferon biosynthetic process
GO:0045354 regulation of interferon-alpha biosynthetic process
GO:0045356 positive regulation of interferon-alpha biosynthetic process
GO:0045357 regulation of interferon-beta biosynthetic process
GO:0045359 positive regulation of interferon-beta biosynthetic process
GO:0045414 regulation of interleukin-8 biosynthetic process
GO:0045416 positive regulation of interleukin-8 biosynthetic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051607 defense response to virus
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071496 cellular response to external stimulus
GO:0090316 positive regulation of intracellular protein transport
GO:0098542 defense response to other organism
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0003725 double-stranded RNA binding
GO:0003727 single-stranded RNA binding
GO:0008144 drug binding
GO:0035197 siRNA binding
Cellular Component GO:0005765 lysosomal membrane
GO:0010008 endosome membrane
GO:0030139 endocytic vesicle
GO:0032009 early phagosome
GO:0036019 endolysosome
GO:0036020 endolysosome membrane
GO:0043235 receptor complex
GO:0044440 endosomal part
GO:0045335 phagocytic vesicle
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-975110: TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1679131: Trafficking and processing of endosomal TLR
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TLR7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TLR7 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26994345Breast CarcinomaInhibit immunityThe delivery of let-7b could reactivate TAMs/TIDCs by acting as a TLR-7 agonist and suppressing IL-10 production in vitro. In a breast cancer mouse model, let-7b delivered by this system efficiently reprogrammed the functions of TAMs/TIDCs, reversed the suppressive tumor microenvironment, and inhibited tumor growth.
25825448Non-Small Cell Lung CarcinomaPromote immunity (T cell function)The ability of TLR7/8 agonists to reverse mMDSC-mediated immune suppression suggests that they might be useful adjuncts for tumor immunotherapy.
23086756B-Cell cell lymphoma; T-Cell cell lymphomaPromote immunity (T cell function)In combination, TLR7/RT therapy leads to the expansion of tumor antigen-specific CD8(+) T cells and improved survival. Furthermore, those mice that achieve long-term clearance of tumor after TLR7/RT therapy are protected from subsequent tumor rechallenge by the generation of a tumor-specific memory immune response.
19380767MesotheliomaPromote immunityTopical application of tumors with the TLR7 agonist imiquimod is an effective adjunct treatment for a range of primary dermatological cancers.?These results demonstrate that antitumor responses induced by locally delivered TLR7 agonists can be harnessed systemically for treating distal tumor.
19620771Ovarian CarcinomaPromote immunityHere we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulatory DCs expressing CD11c and programmed cell death 1-ligand 1 (PD-L1) at ovarian cancer locations in mice. PEI triggered robust and selective TLR5 activation in vitro and elicited the production of hallmark TLR5-inducible cytokines in WT mice, but not in Tlr5-/- littermates. Our results demonstrate that the intrinsic TLR5 and TLR7 stimulation of siRNA-PEI nanoparticles synergizes with the gene-specific silencing activity of siRNA to transform tumor-infiltrating regulatory DCs into DCs capable of promoting therapeutic antitumor immunity.
19890064LymphomaPromote immunity (NK cell function)Use of gene-deficient mice showed that NK activation is entirely TLR7-dependent. Reconstitution of TLR7-deficient mice with wild-type dendritic cells restores NK activation upon treatment with immunostimulatory RNA oligonucleotides.
19887600Pancreatic CarcinomaPromote immunity (T cell function)Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Poly(I:C) treatment of pancreatic adenocarcinomas followed by coculture with gammadelta T cells resulted in an upregulation of CD54 on the tumor cells. The interaction of CD54 and the corresponding ligand CD11a/CD18 expressed on gammadelta T cells is responsible for triggering effector function in gammadelta T cells.
24954733melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyPoly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
24893628Skin Basal Cell CarcinomaPromote immunityImiquimod is a Toll-like receptor 7 agonist used topically to treat external genital warts and basal cell carcinoma.
29573820lymphomaPromote immunitySmall molecule TLR7/8 agonist hold high potential for this purpose, but suffer from an undesirable pharmacokinetic profile, resulting in systemic inflammatory responses.
23995793Skin Basal Cell CarcinomaPromote immunity (T cell function)It is reported to be a TLR7 and TLR8 agonist and, as such, initiates a Th1 immune response by activating sentinel cells in the vicinity of the tumour.
20065291Skin Basal Cell CarcinomaPromote immunity (T cell function); essential for immunotherapyToll-like receptor (TLR) agonists are prime candidates to fulfill this role because they induce innate immune activation and promote adaptive immune responses. The successful application of the TLR7 agonist R837 for treatment of basal cell carcinoma shows the potential for exploiting this pathway in tumor immunotherapy. Imidazoquinolines like R837 and stimulatory ssRNA oligonucleotides both trigger TLR7-mediated immune activation, but little is known about their comparative ability to promote immunity induction.
29157965Skin CarcinomaPromote immunitySmall-molecule agonists for the Toll-like receptors (TLR) 7 and 8 are effective for the immunotherapy of skin cancer when used as topical agents. Thus, polymer-based nanoparticles represent a promising delivery system that allows lymph node targeting for small-molecule TLR7 agonists in the context of systemic cancer immunotherapy.
16034143MelanomaPromote immunity (T cell function)Activation of innate immune cells through TLR triggers immunomodulating events that enhance cell-mediated immunity, raising the possibility that ligands to these receptors might act as adjuvants in conjunction with T cell activating vaccines. In this report, topical imiquimod, a synthetic TLR7 agonist, significantly enhanced the protective antitumor effects of a live, recombinant listeria vaccine against murine melanoma.
22767669Breast CarcinomaPromote immunityTopical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immune-mediated rejection of primary skin malignancies when topically applied.
20515950Colon Carcinoma; Lung CarcinomaPromote immunity (T cell function)Peritoneal administration of dual TLR7/8 agonist in mice bearing CT26.CL25 colon carcinomas had potent dose-dependent antitumor activity, which was associated with a marked decrease in CD4(+)CD25(+)Foxp3(+) T regulatory cells and a significant increase in tumor antigen-specific IFN-gamma-secreting effector cell responses in splenocytes and local tumor-infiltrating cells. Administration of TLR7/8 agonist effectively prevented lung metastasis of tumors in the CT26.CL25 pulmonary metastasis model. These studies show that the dual TLR7/8 agonist induced Th1-type immune responses and potent antitumor activity in mice via TLR7 and through the MyD88-dependent pathway.
20237413Lung CarcinomaInhibit immunityTriggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. Stimulation with TLR7 or TLR8 agonists led to activated NF-kappaB, upregulated expression of the antiapoptotic protein Bcl-2, increased tumor cell survival, and chemoresistance.
29739434Gastric CarcinomaPromote immunityGastric cancer vaccines were synthesized by the covalent attachment of our TLR7 agonist with the gastric cancer antigen MG7-Ag tetra-epitope, leading to T7 - ML (linear tetra-epitope) and T7 - MB (branched tetra-epitope). In vitro, rapid TNF-α and IL-12 inductions occurred in BMDCs treated with the vaccines. In vivo, among all the vaccines tested, T7 - MB most effectively reduced EAC tumor burdens and induced CTLs, antibodies and ADCC activity in BALB/c mice.
18794336Squamous Cell CarcinomaPromote immunityTumors treated with the Toll-like receptor (TLR)7 agonist imiquimod before excision showed induction of E-selectin on tumor vessels, recruitment of CLA(+) CD8(+) T cells, and histological evidence of tumor regression. Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.
17535975Skin Basal Cell CarcinomaPromote immunityTumoricidal activity of TLR7/8-activated inflammatory dendritic cells. The biological relevance of this observation can be deduced from our further findings that peripheral blood-derived CD11c(+) mDCs acquired antiperforin and anti-granzyme B reactivity upon TLR7/8 stimulation and could use these molecules to effectively lyse major histocompatibility complex (MHC) class I(lo) cancer cell lines.
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TLR7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TLR7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2230.605
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6370.422
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0880.903
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3890.227
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.60.597
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1250.926
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4560.359
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0120.364
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2420.855
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.090.0629
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6170.123
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0030.989
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TLR7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TLR7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TLR7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TLR7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TLR7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TLR7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TLR7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTLR7
Nametoll-like receptor 7
Aliases TLR7-like; toll-like receptor 7-like
Chromosomal LocationXp22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TLR7 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TLR7.
ID Name Drug Type Targets #Targets
DB00724ImiquimodSmall MoleculeTLR7, TLR82
DB01611HydroxychloroquineSmall MoleculeTLR7, TLR92
DB04860IsatoribineSmall MoleculeTLR71
DB05127ANA971Small MoleculeTLR71
DB05475GolotimodSmall MoleculeTLR2, TLR4, TLR7, TLR94
DB06530ResiquimodSmall MoleculeTLR7, TLR82